



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APR 04 2001

RECEIVED

In re application of: Ni et al.

Application No: 09/109,864

Art Unit: 1646

Filed: July 6, 1998

Examiner: Ulm, J.

For: Galectin 11

Attorney Docket No.: PF354P1

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed November 2, 2000, and in accordance with 37 C.F.R. § 1.111, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (a) a Petition For Extension of Time for two months, up to and including April 2, 2001 accompanied by the appropriate fee; (b) a Fee Transmittal Sheet; (c) Exhibit A hereto; and (d) a Second Supplemental Information Disclosure Statement with revised form PTO/SB/08 and a copy of the cited reference B8.

In the Claims

Please cancel claims 111 and 126, without prejudice.

Please amend claims 44 and 73 to read as follows. In accordance with 37 C.F.R. § 1.121(c)(1)(ii), a version of claims 44 and 73 as amended below showing the changes made is set forth in the Appendix, below.

44. (Twice amended) An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of:
- (a) a polynucleotide sequence encoding the amino acid sequence of amino acid residues 65 to 70 of SEQ ID NO:2;
 - (b) a polynucleotide sequence encoding the amino acid sequence of amino acid residues 118 to 124 of SEQ ID NO:2;